NEULANDLAB2021-10-012021-12-31in-bse-fin:OneOperatingExpenses01Member NEULANDLAB2021-10-012021-12-31in-bse-fin:OneOperatingExpenses02Member NEULANDLAB2021-10-012021-12-31in-bse-fin:FourOperatingExpenses01Member NEULANDLAB2021-10-012021-12-31in-bse-fin:FourOperatingExpenses02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares NEULANDLAB 2021-04-01 2022-03-31 2022-01-07 INR Lakhs Third quarter Single segment Manufacturing of Active Pharmaceuticals Ingredients 2021-10-01 2021-12-31 Unaudited Standalone 2364698000.00 19001000.00 2383699000.00 958452000.00 0.00 102690000.00 456927000.00 33216000.00 127748000.00 523685000.00 2202718000.00 180981000.00 0.00 180981000.00 44431000.00 9227000.00 53658000.00 0.00 127323000.00 0.00 0.00 0.00 0.00 127323000.00 -3636000.00 123687000.00 0.00 0.00 129005000.00 10 9.92 9.92 0.00 0.00 9.92 9.92 NOTES 1 The financial results for the quarter and nine month ended 31 December 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 01 February 2022. 2 The financial results have been prepared in accordance with the Indian Accounting Standards Ind AS prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. 3 The operations of the Company are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 Operating Segments. 4 The Company continues to evaluate the impact of the pandemic on all aspects of its business, including impact on customers, employees, vendors and business partners. The Company has taken several business continuity measures including transport for factory employees, work from home, following the social distancing norms.The Company has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of goodwill, investments, inventory, based on the information available to date, both internal and external, while preparing the financial results for the period ended 31 December 2021. Based on the assessment done by the management of the Company, there is no significant/material impact of COVID-19 on the results for the period ended 31 December 2021. The Company has been closely monitoring any material changes to future economic conditions. 5 The EPS for quarters has not been annualised. 6 The previous period figures have been regrouped/rearranged wherever necessary to make it comparable with the current period. Single segment 2021-04-01 2021-12-31 Unaudited Standalone 6952041000.00 42425000.00 6994466000.00 3398403000.00 0.00 -353089000.00 1333228000.00 107244000.00 365841000.00 1566658000.00 6418285000.00 576181000.00 0.00 576181000.00 133915000.00 25198000.00 159113000.00 0.00 417068000.00 0.00 0.00 0.00 0.00 417068000.00 -41305000.00 375763000.00 0.00 0.00 129005000.00 10 32.51 32.51 0.00 0.00 32.51 32.51 Manufacturing expenses 338799000.00 Other expenses 184886000.00 Manufacturing expenses 989999000.00 Other expenses 576659000.00